Lastly, a new NAFLD treatment opportunity has emerged in the form of IONIS-DGAT2Rx, which is an antisense oligonucleotide inhibitor of diacylglycerol-o-acyltransferase 2 (DGAT2). Here, DGAT2 is linked to metabolic dysfunction-associated steatotic liver disease.